$12.48
+0.44
(+3.65%)▲
Revenue is up for the last 4 quarters, 85.52M → 99.02M (in $), with an average increase of 4.7% per quarter
Netprofit is up for the last 4 quarters, -342.82M → -30.43M (in $), with an average increase of 228.2% per quarter
5.81%
Downside
Day's Volatility :8.02%
Upside
2.35%
58.01%
Downside
52 Weeks Volatility :69.19%
Upside
26.63%
Period | Accolade Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -2.82% | 0.7% | -6.8% |
6 Months | 34.23% | -8.3% | -6.0% |
1 Year | 106.52% | -1.9% | -4.6% |
3 Years | -59.46% | 25.3% | 25.9% |
Market Capitalization | 866.7M |
Book Value | $6.48 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -6.63 |
Wall Street Target Price | 15.53 |
Profit Margin | -126.58% |
Operating Margin TTM | -42.83% |
Return On Assets TTM | -8.88% |
Return On Equity TTM | -69.14% |
Revenue TTM | 363.1M |
Revenue Per Share TTM | 5.1 |
Quarterly Revenue Growth YOY | 5.6000000000000005% |
Gross Profit TTM | 165.3M |
EBITDA | -110.3M |
Diluted Eps TTM | -6.63 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.49 |
EPS Estimate Next Year | -1.96 |
EPS Estimate Current Quarter | -0.42 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 24.44%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 76.8M | - |
Net Income | -61.3M | - |
Net Profit Margin | -79.77% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 94.8M | ↑ 23.41% |
Net Income | -56.5M | ↓ 7.82% |
Net Profit Margin | -59.59% | ↑ 20.18% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 132.5M | ↑ 39.76% |
Net Income | -51.4M | ↓ 9.08% |
Net Profit Margin | -38.76% | ↑ 20.83% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 170.4M | ↑ 28.57% |
Net Income | -50.7M | ↓ 1.39% |
Net Profit Margin | -29.73% | ↑ 9.03% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 310.0M | ↑ 81.98% |
Net Income | -123.1M | ↑ 143.08% |
Net Profit Margin | -39.71% | ↓ 9.98% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 363.1M | ↑ 17.13% |
Net Income | -459.7M | ↑ 273.32% |
Net Profit Margin | -126.58% | ↓ 86.87% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 83.5M | ↑ 13.87% |
Net Income | 22.5M | ↓ 136.08% |
Net Profit Margin | 26.97% | ↑ 112.06% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 93.8M | ↑ 12.35% |
Net Income | -34.6M | ↓ 253.56% |
Net Profit Margin | -36.86% | ↓ 63.83% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 85.5M | ↓ 8.78% |
Net Income | -342.8M | ↑ 892.08% |
Net Profit Margin | -400.83% | ↓ 363.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 87.6M | ↑ 2.47% |
Net Income | -46.5M | ↓ 86.43% |
Net Profit Margin | -53.08% | ↑ 347.75% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 90.9M | ↑ 3.77% |
Net Income | -39.9M | ↓ 14.3% |
Net Profit Margin | -43.84% | ↑ 9.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 99.0M | ↑ 8.88% |
Net Income | -30.4M | ↓ 23.67% |
Net Profit Margin | -30.73% | ↑ 13.11% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 47.1M | - |
Total Liabilities | 230.8M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 65.8M | ↑ 39.68% |
Total Liabilities | 296.4M | ↑ 28.43% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 124.4M | ↑ 89.19% |
Total Liabilities | 148.2M | ↓ 50.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 475.5M | ↑ 282.2% |
Total Liabilities | 84.7M | ↓ 42.87% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 170.35% |
Total Liabilities | 429.7M | ↑ 407.59% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 903.1M | ↓ 29.75% |
Total Liabilities | 429.3M | ↓ 0.11% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 0.51% |
Total Liabilities | 474.7M | ↓ 11.48% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 1.76% |
Total Liabilities | 429.7M | ↓ 9.46% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 944.5M | ↓ 26.53% |
Total Liabilities | 409.9M | ↓ 4.6% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 931.7M | ↓ 1.35% |
Total Liabilities | 425.4M | ↑ 3.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 913.8M | ↓ 1.92% |
Total Liabilities | 427.8M | ↑ 0.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 903.1M | ↓ 1.17% |
Total Liabilities | 429.3M | ↑ 0.34% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -38.3M | - |
Investing Cash Flow | -7.2M | - |
Financing Cash Flow | 15.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.5M | ↓ 56.78% |
Investing Cash Flow | -3.1M | ↓ 56.41% |
Financing Cash Flow | 48.8M | ↑ 224.71% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -34.2M | ↑ 106.96% |
Investing Cash Flow | -3.5M | ↑ 12.92% |
Financing Cash Flow | 28.2M | ↓ 42.21% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↓ 26.32% |
Investing Cash Flow | -2.4M | ↓ 31.18% |
Financing Cash Flow | 428.4M | ↑ 1417.91% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -62.4M | ↑ 147.11% |
Investing Cash Flow | -263.6M | ↑ 10779.61% |
Financing Cash Flow | 257.9M | ↓ 39.79% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -40.7M | ↓ 34.72% |
Investing Cash Flow | -7.2M | ↓ 97.26% |
Financing Cash Flow | 3.2M | ↓ 98.77% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.4M | ↑ 94.22% |
Investing Cash Flow | 721.0K | ↓ 98.89% |
Financing Cash Flow | 2.7M | ↓ 41.93% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.3M | ↓ 89.34% |
Investing Cash Flow | -532.0K | ↓ 173.79% |
Financing Cash Flow | 2.7M | ↑ 0.26% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.5M | ↑ 1233.67% |
Investing Cash Flow | -1.3M | ↑ 139.1% |
Financing Cash Flow | 1.5M | ↓ 43.88% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.0M | ↓ 90.17% |
Investing Cash Flow | -1.6M | ↑ 28.3% |
Financing Cash Flow | -370.0K | ↓ 124.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -35.2M | ↑ 1074.51% |
Investing Cash Flow | -1.9M | ↑ 17.1% |
Financing Cash Flow | 3.1M | ↓ 941.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.9M | ↓ 179.37% |
Investing Cash Flow | -2.4M | ↑ 26.27% |
Financing Cash Flow | -1.1M | ↓ 134.99% |
Sell
Neutral
Buy
Accolade Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Accolade Inc | -7.53% | 34.23% | 106.52% | -59.46% | -59.46% |
![]() R1 RCM Inc | 4.57% | 80.16% | -22.69% | 52.87% | 104.66% |
![]() 10X Genomics Inc | 0.1% | 32.58% | 13.7% | -35.99% | -0.55% |
![]() Veeva Systems Inc. | -7.94% | -13.44% | -1.28% | -24.32% | 107.7% |
![]() GE HEALTHCARE TECHNOLOGIES INC. | -1.57% | 31.44% | 31.44% | 31.44% | 31.44% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Accolade Inc | NA | NA | NA | -6.49 | -0.69 | -0.09 | 0.0 | 6.48 |
![]() R1 RCM Inc | 128.18 | NA | 0.77 | 0.04 | -0.06 | 0.04 | 0.0 | 6.5 |
![]() 10X Genomics Inc | NA | NA | NA | -1.42 | -0.22 | -0.11 | 0.0 | 6.91 |
![]() Veeva Systems Inc. | 53.48 | 53.48 | 1.27 | 4.18 | 0.15 | 0.07 | 0.0 | 23.48 |
![]() GE HEALTHCARE TECHNOLOGIES INC. | 21.01 | 21.01 | NA | 3.73 | 0.16 | 0.06 | 0.0 | 14.72 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Accolade Inc | Buy | $866.7M | -59.46% | NA | -126.58% |
![]() R1 RCM Inc | Buy | $6.7B | 104.66% | 128.18 | -4.41% |
![]() 10X Genomics Inc | Buy | $6.3B | -0.55% | NA | -32.51% |
![]() Veeva Systems Inc. | Buy | $26.2B | 107.7% | 53.48 | 22.63% |
![]() GE HEALTHCARE TECHNOLOGIES INC. | Buy | $35.4B | 31.44% | 21.01 | 9.17% |
ARK Investment Management LLC
BlackRock Inc
JPMorgan Chase & Co
Brown Advisory Holdings Inc
Vanguard Group Inc
Bellevue Group AG
Accolade Inc’s price-to-earnings ratio stands at None
Read MoreAccolade, Inc. of Pennsylvania provides healthcare related information for self-insured companies. The Company assists employees and their families to make healthcare decisions through its health assistants. Accolade serves customers in the United States.
Organization | Accolade Inc |
Employees | 2370 |
CEO | Mr. Rajeev Singh |
Industry | Health Services |
Janus International Group, Inc.
$8.94
+1.25%
JPMORGAN BETABUILDERS US SC
$53.55
+1.09%
BJ's Restaurants
$30.22
+1.48%
American Axle & Manufacturing Holdings I
$6.85
+1.48%
Two Harbors Investment Corp.
$12.86
+3.38%
Telecom Argentina S.A.
$5.10
+5.15%
NuShares ESG International Developed Markets Equity ETF
$28.37
+1.65%
GAMIDA CELL LTD
$2.16
+2.86%
Patrick Industries Inc.
$67.99
+3.75%